Examination of the mechanisms of osteolysis in patients with metastatic breast cancer

Oncology Reports

Volumn 21, Issue 5, 2009, Pages 1153-1159

  Trinkaus, Mateya ^a   Ooi, Wei Seong ^b   Amir, Ethan ^a   Popovic, Snezana ^c   Kalina, Marion ^d   Kahn, Hariette ^b   Singh, Gurmit ^d   Gainford, Mary Corona ^e   Clemons, Mark ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d JURAVINSKI CANCER CENTRE   (Canada)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bone metastases; Breast cancer; Osteolysis; Receptor activator of nuclear factor B ligand; Vascular endothelial growth factor

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARAFFIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EMBEDDING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MEDICAL RESEARCH; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67649352528     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000335     Document Type: Article

References (54)

1. Ferlay J, Bray F, Pisani P, et al: Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0: IARC CancerBase no. 5, IARC Press, Lyon, 2004.
2. Coleman RE: Skeletal complications of malignancy: Cancer 80: 1588-1594, 1997.
3. Healey JH and Brown HK: Complications of bone metastases. Surgical management. Cancer 88: 2940-2951, 2000.
4. Coleman RE and Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66, 1987.
5. Plunkett TA, Smith P and Rubens RD: Risk of complications from bone metastases in breast cancer implications for management. Eur J Cancer 36: 476-482, 2000.
6. Burgess T, Qian YX, Kaufman S, et al: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145: 527-538, 1999.
7. Lacey DL, Tan HL, Lu J, et al: Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157: 435-448, 2000.
8. O'Brien EA, Williams J and Marshall MJ: Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 274: 281-290, 2000.
9. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998.
10. Schneeweis LA, Willard D and Milla ME: Functional dissociation of osteoprotegerin and its interaction with receptor activator of NF-?B ligand. J Biol Chem 280: 41155-41164, 2005.
11. Yuan YY, Lau AG, Kostenuik PJ, Morony S, Adamu S, Asuncion F and Bateman TA: Soluble RANKL has detrimental effects on cortical and trabecular bone volume, mineralization and bone strength in mice. J Bone Miner Res 20: S161-S162, 2005.
12. Yuan YY, Kostenuik PJ, Ominsky MS, et al: Skeletal deterioration induced by RANKL infusion: A model for high-turnover bone disease. Osteoporos Int (In press).
13. Yuan YY, Kostenuik PJ, Morony S, Simionescu DT, Basalyga DM and Bateman TA: RANKL infusion as a disease model: Implications for bone and vascular systems. J Bone Miner Res 21: S163, 2006.
14. Bucay N, Sarosi I, Dunstan CR, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268, 1998.
15. Mizuno A, Amizuka N, Irie K, et al: Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247: 610-615, 1998.
16. Nakamura M, Udagawa N, Matsuura S, et al: Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144: 5441-5449, 2003.
17. Kitazawa S and Kitazawa R: RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198: 228-236, 2002.
18. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ and Gillespie MT: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458, 1999.
19. Chikatsu N, Takeuchi Y, Tamura Y, et al: Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 267: 632-637, 2000.
20. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC and Abe E: Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100: 18-24, 2001.
21. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL and Dunstan CR: A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1, TNF-α, PTH, PTHrP, and 1,25(OH)2D3. J Bone Miner Res 14: 1478-1485, 1999.
22. Fleisch H: Bisphosphonates: mechanism of action. Endocr Rev 9: 80-100, 1998.
23. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176, 2001.
24. Lipton A, Theriault R, Hortobagyi GN, et al: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast cancer and osteolytic bone metastases - long term follow up of two randomized controlled trials. Cancer 88: 1082-1090, 2000.
25. Galasko CSB: Mechanisms of bone destruction in the development of skeletal metastases. Nature 263: 507-508, 1976.
26. Parfitt AM, Drezner MK, Glorieux FH, et al: Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Rel Res 2: 595-610, 1987.
27. Waterman EA, Cross NA, Lippitt JM, et al: The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers. Int J Cancer 121: 1958-1966, 2007.
28. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571-573, 1889.
29. Orr FW, Varani J, Gondek MD, Ward PA and Mundy GR: Chemotactic responses of tumor cells to products of resorbing bone. Science 203: 176-179, 1979.
30. Kohno N, Aogi K, Minami H, et al: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23: 3314-3321, 2005.
31. Hortobagyi GN, Theriault RL, Lipton A, et al: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16: 2038-2044, 1998.
32. Theriault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846-854, 1999.
33. Conte PF, Latreille J, Mauriac L, et al: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14: 2552-2559, 1996.
34. Hultborn R, Gundersen S, Ryden S, et al: Efficacy of pamidronate in breast cancer with bone metastases: a randomized, doubleblind placebo-controlled multicenter study. Anticancer Res 19: 3383-3392, 1999.
35. McCloskey E, Guest JF and Kanis J: The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 61: 1253-1274, 2001.
36. Mundy GR, Raisz LG, Cooper RA, Schechter GP and Salmon SE: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291: 1041-1046, 1974.
37. Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MW and Holen I: Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL) and receptor activator of nuclear factor KappaB ligand (RANKL) in human breast tumours. J Clin Pathol 59: 56-63, 2006.
38. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D and Rédini F: DU145 human prostate cancer cells express functional receptor activator of NFKB: New insights in the prostate cancer bone metastasis process. Bone 49: 981-990, 2007.
39. Morrisey C, Kostenuik PJ, Brown LG, Vessella RL and Corey E: Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer 7: 148, 2007.
40. Kostenuik PJ: Revisiting the seed and soil theory of bone metastasis: New tools, same answer. J Musculoskel Neuron Interact 4: 375-376, 2004.
41. Aldridge SE, Lennard TW, Williams JR and Birch MA: Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer 92: 1531-1537, 2005.
42. Santini D Vincenzi B, Dicuonzo G, et al: Zoledronic Acid induces significant long lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9: 2893-2897, 2003.
43. Vukmirovic-Popovic S, Colterjohn N, Lhotak S, Duivenvoorden WC, Orr FW and Singh G: Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma. Bone 31: 529-535, 2002.
44. Pataki A, Müller K, Green JR, Ma YF, Li QN and Jee WS: Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 249: 458-468, 1997.
45. Fisher JE, Rogers MJ, Halasy JM, et al: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96: 133-138, 1999.
46. Chavassieux PM, Arlot ME, Reda C, Wel L, Yates AJ and Meunier PJ: Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 1475-1480, 1997.
47. Bravenboer N, Papapoulos SE, Holzmann P, Hamdy NAT, Netelenbos JC and Lips P: Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int 9: 489-493, 1999.
48. Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski J, Seibel MJ and Dunstan CR: Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumor actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40: 471-478, 2007.
49. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL and Corey E: Comparison of Fc-osteoprotegerin and zoledronic acid activities suggest that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis 8: 253-259, 2005.
50. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y and Epstein J: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is depenendent on osteoclast activity. Br J Haematol 116: 278-290, 2002.
51. Phadke PA, Mercer RR, Harms JF, et al: Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res 12: 1431-1440, 2006.
52. Bekker PJ: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Rel 29: 2274-2281, 2005.
53. Suarez T, Fizazi K, Rahim Y, Wilson J, Fan M, Jun S and Lipton A: A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. J Clin Oncol ASCO Annual Meeting Proc Part I 24: Abs 8562, 2006.
54. McClung MR, Lewiecki EM, Cohen SB, et al: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821-831, 2006.